{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:53:26Z","timestamp":1783464806189,"version":"3.55.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J01295"],"award-info":[{"award-number":["2025J01295"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J011458"],"award-info":[{"award-number":["2024J011458"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J08364"],"award-info":[{"award-number":["2024J08364"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Provincial Health Technology Project,China","award":["2022CXA057"],"award-info":[{"award-number":["2022CXA057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11897-025-00722-z","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:29:42Z","timestamp":1761726582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review"],"prefix":"10.1007","volume":"22","author":[{"given":"Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"2","key":"722_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","volume":"392","author":"A Cannata","year":"2025","unstructured":"Cannata A, McDonagh TA. Heart failure with preserved ejection fraction. N Engl J Med. 2025;392(2):173\u201384. https:\/\/doi.org\/10.1056\/NEJMcp2305181.","journal-title":"N Engl J Med"},{"issue":"2","key":"722_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10741-023-10338-x","volume":"29","author":"W Meifang","year":"2024","unstructured":"Meifang W, Ying W, Wen C, et al. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials. Heart Fail Rev. 2024;29(2):305\u201320. https:\/\/doi.org\/10.1007\/s10741-023-10338-x.","journal-title":"Heart Fail Rev"},{"issue":"10","key":"722_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827\u201338. https:\/\/doi.org\/10.1001\/jama.2023.2020.","journal-title":"JAMA"},{"key":"722_CR4","doi-asserted-by":"publisher","unstructured":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021. Lancet (London, England). 2025;405(10481):813\u201338. https:\/\/doi.org\/10.1016\/s0140-6736(25)00355-1.","DOI":"10.1016\/s0140-6736(25)00355-1"},{"issue":"10456","key":"722_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/s0140-6736(24)01210-8","volume":"404","author":"I Lingvay","year":"2024","unstructured":"Lingvay I, Cohen RV, Roux CWL, Sumithran P. Obesity in adults. Lancet (London, England). 2024;404(10456):972\u201387. https:\/\/doi.org\/10.1016\/s0140-6736(24)01210-8.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"722_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/circulationaha.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6\u201319. https:\/\/doi.org\/10.1161\/circulationaha.116.026807.","journal-title":"Circulation"},{"issue":"7","key":"722_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023;25(7):936\u201355. https:\/\/doi.org\/10.1002\/ejhf.2894.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"722_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/hco.0000000000001113","volume":"39","author":"R Verma","year":"2024","unstructured":"Verma R, Dhingra NK, Connelly KA. Obesity\/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials. Curr Opin Cardiol. 2024;39(2):92\u20137. https:\/\/doi.org\/10.1097\/hco.0000000000001113.","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"722_CR9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.mayocp.2018.11.037","volume":"94","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV, Lewis GD, Shah SJ, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc. 2019;94(7):1199\u2013209. https:\/\/doi.org\/10.1016\/j.mayocp.2018.11.037.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"722_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/s0735-1097(01)01448-6","volume":"38","author":"TB Horwich","year":"2001","unstructured":"Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38(3):789\u201395. https:\/\/doi.org\/10.1016\/s0735-1097(01)01448-6.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"722_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.cardfail.2019.03.007","volume":"25","author":"AR Vest","year":"2019","unstructured":"Vest AR, Chan M, Deswal A, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America scientific statements committee. J Card Fail. 2019;25(5):380\u2013400. https:\/\/doi.org\/10.1016\/j.cardfail.2019.03.007.","journal-title":"J Card Fail"},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","volume":"82","author":"PL Alebna","year":"2024","unstructured":"Alebna PL, Mehta A, Yehya A, et al. Update on obesity, the obesity paradox, and obesity management in heart failure. Prog Cardiovasc Dis. 2024;82:34\u201342. https:\/\/doi.org\/10.1016\/j.pcad.2024.01.003.","journal-title":"Prog Cardiovasc Dis"},{"key":"722_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10439-1","author":"A Vacca","year":"2024","unstructured":"Vacca A, Wang R, Nambiar N, et al. Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities. Heart Fail Rev. 2024. https:\/\/doi.org\/10.1007\/s10741-024-10439-1.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"722_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315(1):36\u201346. https:\/\/doi.org\/10.1001\/jama.2015.17346.","journal-title":"JAMA"},{"issue":"21","key":"722_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.022930","volume":"10","author":"EC El Hajj","year":"2021","unstructured":"El Hajj EC, El Hajj MC, Sykes B, et al. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10(21):e022930. https:\/\/doi.org\/10.1161\/jaha.121.022930.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"722_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1212914.","journal-title":"N Engl J Med"},{"issue":"3","key":"722_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/obr.12113","volume":"15","author":"LM Warkentin","year":"2014","unstructured":"Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obes Rev. 2014;15(3):169\u201382. https:\/\/doi.org\/10.1111\/obr.12113.","journal-title":"Obes Rev"},{"issue":"1","key":"722_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","volume":"33","author":"D Eisenberg","year":"2023","unstructured":"Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Obes Surg. 2023;33(1):3\u201314. https:\/\/doi.org\/10.1007\/s11695-022-06332-1.","journal-title":"Obes Surg"},{"issue":"2","key":"722_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/oby.22038","volume":"26","author":"D Mikhalkova","year":"2018","unstructured":"Mikhalkova D, Holman SR, Jiang H, et al. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity. 2018;26(2):284\u201390. https:\/\/doi.org\/10.1002\/oby.22038.","journal-title":"Obesity"},{"issue":"2","key":"722_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cardfail.2019.09.010","volume":"26","author":"WL Miller","year":"2020","unstructured":"Miller WL, Borlaug BA. Impact of obesity on volume status in patients with ambulatory chronic heart failure. J Card Fail. 2020;26(2):112\u20137. https:\/\/doi.org\/10.1016\/j.cardfail.2019.09.010.","journal-title":"J Card Fail"},{"issue":"9866","key":"722_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/s0140-6736(12)61819-4","volume":"381","author":"FH Messerli","year":"2013","unstructured":"Messerli FH, Bangalore S. Diuretic-based regimens for obese patients? Lancet (London, England). 2013;381(9866):512\u20133. https:\/\/doi.org\/10.1016\/s0140-6736(12)61819-4.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"722_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","volume":"329","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214\u201323. https:\/\/doi.org\/10.1001\/jama.2022.23924.","journal-title":"JAMA"},{"issue":"13","key":"722_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387(13):1185\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2203094.","journal-title":"N Engl J Med"},{"issue":"2","key":"722_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ejhf.2377","volume":"24","author":"M Obokata","year":"2022","unstructured":"Obokata M, Reddy YNV, Melenovsky V, et al. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. Eur J Heart Fail. 2022;24(2):353\u201361. https:\/\/doi.org\/10.1002\/ejhf.2377.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"722_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ejhf.2415","volume":"24","author":"LMG Meems","year":"2022","unstructured":"Meems LMG, van Veldhuisen DJ, de Boer RA. Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out\u2026?! Eur J Heart Fail. 2022;24(2):362\u20134. https:\/\/doi.org\/10.1002\/ejhf.2415.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"722_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cardfail.2019.11.018","volume":"26","author":"B Upadhya","year":"2020","unstructured":"Upadhya B, Amjad A, Stacey RB. Optimizing the management of obese HFpEF phenotype: can we mind both the heart and the kidney? J Card Fail. 2020;26(2):108\u201311. https:\/\/doi.org\/10.1016\/j.cardfail.2019.11.018.","journal-title":"J Card Fail"},{"issue":"2","key":"722_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cardfail.2019.09.015","volume":"26","author":"YNV Reddy","year":"2020","unstructured":"Reddy YNV, Obokata M, Testani JM, et al. Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction. J Card Fail. 2020;26(2):101\u20137. https:\/\/doi.org\/10.1016\/j.cardfail.2019.09.015.","journal-title":"J Card Fail"},{"key":"722_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132304","volume":"412","author":"A Abdin","year":"2024","unstructured":"Abdin A, B\u00f6hm M, Shahim B, et al. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies. Int J Cardiol. 2024;412:132304. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132304.","journal-title":"Int J Cardiol"},{"issue":"1","key":"722_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ehf2.14562","volume":"11","author":"Y Wu","year":"2024","unstructured":"Wu Y, Song M, Wu M, Lin L. Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials. ESC Heart Fail. 2024;11(1):13\u201327. https:\/\/doi.org\/10.1002\/ehf2.14562.","journal-title":"ESC Heart Fail"},{"issue":"16","key":"722_CR30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"722_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"722_CR32","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023(37). https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"722_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001062","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022. https:\/\/doi.org\/10.1161\/cir.0000000000001062.","journal-title":"Circulation"},{"issue":"41","key":"722_CR34","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson C, Kondo T, Jhund PS, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43(41):4406\u201317. https:\/\/doi.org\/10.1093\/eurheartj\/ehac481.","journal-title":"Eur Heart J"},{"issue":"4","key":"722_CR35","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/ejhf.3221","volume":"26","author":"N Sattar","year":"2024","unstructured":"Sattar N, Butler J, Lee MMY, et al. Body mass index and cardiorenal outcomes in the EMPEROR-preserved trial: principal findings and meta-analysis with the DELIVER trial. Eur J Heart Fail. 2024;26(4):900\u20139. https:\/\/doi.org\/10.1002\/ejhf.3221.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"722_CR36","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"issue":"3","key":"722_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"MJ Pereira","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219\u201330. https:\/\/doi.org\/10.1007\/s40265-019-1057-0.","journal-title":"Drugs"},{"issue":"25","key":"722_CR38","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1161\/circulationaha.124.069479","volume":"149","author":"JA Naser","year":"2024","unstructured":"Naser JA, Tada A, Harada T, et al. Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction. Circulation. 2024;149(25):2026\u20138. https:\/\/doi.org\/10.1161\/circulationaha.124.069479.","journal-title":"Circulation"},{"issue":"37","key":"722_CR39","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehae534","volume":"45","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV, Melenovsky V, Asokan AK, et al. Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction. Eur Heart J. 2024;45(37):3889\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehae534.","journal-title":"Eur Heart J"},{"issue":"1","key":"722_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","volume":"30","author":"GB Bonfioli","year":"2025","unstructured":"Bonfioli GB, Rodella L, Metra M, Vizzardi E. GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. Heart Fail Rev. 2025;30(1):131\u20136. https:\/\/doi.org\/10.1007\/s10741-024-10450-6.","journal-title":"Heart Fail Rev"},{"issue":"12","key":"722_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"9","key":"722_CR42","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","volume":"29","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29(9):2358\u201365. https:\/\/doi.org\/10.1038\/s41591-023-02526-x.","journal-title":"Nat Med"},{"issue":"3","key":"722_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/circulationaha.123.067505","volume":"149","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Verma S, Borlaug BA, et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149(3):204\u201316. https:\/\/doi.org\/10.1161\/circulationaha.123.067505.","journal-title":"Circulation"},{"issue":"15","key":"722_CR44","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"key":"722_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00304-8","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, van der Meer P, Verma S, et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025. https:\/\/doi.org\/10.1016\/s2213-8587(24)00304-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10437","key":"722_CR46","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/s0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(24)00469-0.","journal-title":"Lancet"},{"issue":"17","key":"722_CR47","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","volume":"84","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, Ostrominski JW, Wang X, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024;84(17):1587\u2013602. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.021.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"722_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","volume":"84","author":"MC Petrie","year":"2024","unstructured":"Petrie MC, Borlaug BA, Butler J, et al. Semaglutide and NT-proBNP in obesity-related HFpEF: insights From the STEP-HFpEF program. J Am Coll Cardiol. 2024;84(1):27\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.022.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"722_CR49","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Butler J, Borlaug BA, et al. Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program. J Am Coll Cardiol. 2024;84(17):1603\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.023.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"722_CR50","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","volume":"84","author":"M Schou","year":"2024","unstructured":"Schou M, Petrie MC, Borlaug BA, et al. Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program. J Am Coll Cardiol. 2024;84(3):247\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.038.","journal-title":"J Am Coll Cardiol"},{"issue":"10456","key":"722_CR51","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s0140-6736(24)01643-x","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(24)01643-x.","journal-title":"Lancet"},{"issue":"9","key":"722_CR52","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.cpcardiol.2024.102697","volume":"49","author":"G Olatunji","year":"2024","unstructured":"Olatunji G, Aderinto N, Kokori E, et al. Can semaglutide offer hope for patients with obesity-related heart failure? Curr Probl Cardiol. 2024;49(9):102697. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102697.","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"722_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"11","key":"722_CR54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"5","key":"722_CR55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"722_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.001","author":"CM Kramer","year":"2024","unstructured":"Kramer CM, Borlaug BA, Zile MM, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.001.","journal-title":"J Am Coll Cardiol"},{"key":"722_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.12.013","author":"K Nasir","year":"2025","unstructured":"Nasir K, Rochitte CE. Unlocking therapeutic potential for cardiac remodeling in obesity-related HFpEF: lessons from the SUMMIT CMR substudy. J Am Coll Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2024.12.013.","journal-title":"J Am Coll Cardiol"},{"key":"722_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03374-z","author":"BA Borlaug","year":"2024","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03374-z.","journal-title":"Nat Med"},{"issue":"11","key":"722_CR59","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2337\/db21-0459","volume":"70","author":"T Borner","year":"2021","unstructured":"Borner T, Geisler CE, Fortin SM, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70(11):2545\u201353. https:\/\/doi.org\/10.2337\/db21-0459.","journal-title":"Diabetes"},{"issue":"10","key":"722_CR60","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/circulationaha.124.072679","volume":"151","author":"MR Zile","year":"2025","unstructured":"Zile MR, Borlaug BA, Kramer CM, et al. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation. 2025;151(10):656\u201368. https:\/\/doi.org\/10.1161\/circulationaha.124.072679.","journal-title":"Circulation"},{"issue":"10","key":"722_CR61","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/circulationaha.125.073439","volume":"151","author":"NJ Pagidipati","year":"2025","unstructured":"Pagidipati NJ. Holistic view of Tirzepatide\u2019s role in obesity-related HFpEF. Circulation. 2025;151(10):669\u201371. https:\/\/doi.org\/10.1161\/circulationaha.125.073439.","journal-title":"Circulation"},{"issue":"15","key":"722_CR62","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731.","journal-title":"N Engl J Med"},{"issue":"3","key":"722_CR63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","volume":"8","author":"JB Cohen","year":"2020","unstructured":"Cohen JB, Schrauben SJ, Zhao L, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart failure. 2020;8(3):172\u201384. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.009.","journal-title":"JACC Heart failure"},{"key":"722_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","volume":"146","author":"K Elkholey","year":"2021","unstructured":"Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2021;146:36\u201347. https:\/\/doi.org\/10.1016\/j.amjcard.2021.01.018.","journal-title":"Am J Cardiol"},{"issue":"24","key":"722_CR65","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"23","key":"722_CR66","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"16","key":"722_CR67","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"},{"issue":"2","key":"722_CR68","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","volume":"85","author":"JH Butt","year":"2025","unstructured":"Butt JH, Henderson AD, Jhund PS, et al. Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF. J Am Coll Cardiol. 2025;85(2):140\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.111.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"722_CR69","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/hco.0000000000001214","volume":"40","author":"TA Costa","year":"2025","unstructured":"Costa TA, Harrington JL. Advances in the management of obesity and heart failure: latest evidence from clinical trials. Curr Opin Cardiol. 2025;40(3):164\u201371. https:\/\/doi.org\/10.1097\/hco.0000000000001214.","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"722_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ehjcvp\/pvad001","volume":"9","author":"G Filippatos","year":"2023","unstructured":"Filippatos G, Anker SD, August P, et al. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a fidelity analysis. Eur Heart J. 2023;9(2):183\u201391. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad001.","journal-title":"Eur Heart J"},{"issue":"12","key":"722_CR71","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03264-4.","journal-title":"Nat Med"},{"issue":"2","key":"722_CR72","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jacc.2024.11.033","volume":"85","author":"AR Vest","year":"2025","unstructured":"Vest AR, Sauer AJ. Obesity-related heart failure with preserved ejection fraction: weighing the benefit of Finerenone. J Am Coll Cardiol. 2025;85(2):156\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.033.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"722_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ehjcvp\/pvae082","volume":"11","author":"M Komiyama","year":"2025","unstructured":"Komiyama M, Hasegawa K, Rosano GMC. Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors? Eur Heart J. 2025;11(1):3\u20134. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae082.","journal-title":"Eur Heart J"},{"issue":"6","key":"722_CR74","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10557-016-6699-5","volume":"30","author":"LM Lin","year":"2016","unstructured":"Lin LM, Wu Y, Wu MF, Lin JX. Focus on the novel cardiovascular drug LCZ696: from evidence to clinical consideration. Cardiovasc Drugs Ther. 2016;30(6):623\u201333. https:\/\/doi.org\/10.1007\/s10557-016-6699-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"17","key":"722_CR75","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"issue":"5","key":"722_CR76","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/circulationaha.119.044491","volume":"141","author":"JJV McMurray","year":"2020","unstructured":"McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141(5):338\u201351. https:\/\/doi.org\/10.1161\/circulationaha.119.044491.","journal-title":"Circulation"},{"issue":"5","key":"722_CR77","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/circulationaha.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, B LC, et al. Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352\u201361. https:\/\/doi.org\/10.1161\/circulationaha.119.044586.","journal-title":"Circulation."},{"issue":"1","key":"722_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF. Angiotensin-Neprilysin Inhibition in\u00a0Patients With Mildly Reduced or\u00a0Preserved Ejection Fraction and\u00a0Worsening Heart\u00a0Failure. J Am Coll Cardiol. 2023;82(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019.","journal-title":"J Am Coll Cardiol"},{"key":"722_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf057","author":"A Peikert","year":"2025","unstructured":"Peikert A, Vaduganathan M, Claggett BL, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf057.","journal-title":"Eur Heart J"},{"issue":"12","key":"722_CR80","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/s2468-1253(23)00198-x","volume":"8","author":"M Noureddin","year":"2023","unstructured":"Noureddin M, Khan S, Portell F, et al. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2023;8(12):1094\u2013105. https:\/\/doi.org\/10.1016\/s2468-1253(23)00198-x.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"722_CR81","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ejhf.3305","volume":"26","author":"DW Kitzman","year":"2024","unstructured":"Kitzman DW, Lewis GD, Pandey A, et al. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: rationale and design of the Phase 2a HuMAIN trial. Eur J Heart Fail. 2024;26(9):2013\u201324. https:\/\/doi.org\/10.1002\/ejhf.3305.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"722_CR82","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jamacardio.2025.0103","volume":"10","author":"A Pandey","year":"2025","unstructured":"Pandey A, Lewis GD, Borlaug BA, et al. Novel controlled metabolic accelerator for obesity-related HFpEF: the HuMAIN-HFpEF randomized clinical trial. JAMA Cardiol. 2025;10(6):609\u201316. https:\/\/doi.org\/10.1001\/jamacardio.2025.0103.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"722_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.tips.2025.02.005","volume":"46","author":"Y Li","year":"2025","unstructured":"Li Y, Lin Z, Li Y. Visceral obesity and HFpEF: targets and therapeutic opportunities. Trends Pharmacol Sci. 2025;46(4):337\u201356. https:\/\/doi.org\/10.1016\/j.tips.2025.02.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"722_CR84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/s2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"722_CR85","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","volume":"6","author":"VN Rao","year":"2018","unstructured":"Rao VN, Zhao D, Allison MA, et al. Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). JACC Heart failure. 2018;6(12):999\u20131007. https:\/\/doi.org\/10.1016\/j.jchf.2018.07.009.","journal-title":"JACC Heart failure"},{"issue":"12","key":"722_CR86","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jchf.2018.08.007","volume":"6","author":"DW Kitzman","year":"2018","unstructured":"Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF. JACC Heart Fail. 2018;6(12):1008\u201310. https:\/\/doi.org\/10.1016\/j.jchf.2018.08.007.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"722_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100657","volume":"2","author":"SA Goldman","year":"2023","unstructured":"Goldman SA, Requena-Ibanez JA, Devesa A, et al. Uncovering the role of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Adv. 2023;2(9):100657. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100657.","journal-title":"JACC Adv"},{"issue":"8","key":"722_CR88","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","volume":"8","author":"KE Koepp","year":"2020","unstructured":"Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC: Heart Failure. 2020;8(8):657\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.016.","journal-title":"JACC: Heart Failure"},{"issue":"37","key":"722_CR89","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","volume":"44","author":"AK Pandey","year":"2023","unstructured":"Pandey AK, Bhatt DL, Pandey A, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44(37):3640\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehad389.","journal-title":"Eur Heart J"},{"issue":"9","key":"722_CR90","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30(9):2395\u20139. https:\/\/doi.org\/10.1038\/s41591-024-03095-3.","journal-title":"Nat Med"},{"issue":"9","key":"722_CR91","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/ejhf.3270","volume":"26","author":"KH Peck","year":"2024","unstructured":"Peck KH, Dulay MS, Hameed S, et al. Intentional weight loss in overweight and obese patients with heart failure: A systematic review. Eur J Heart Fail. 2024;26(9):1907\u201330. https:\/\/doi.org\/10.1002\/ejhf.3270.","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 3","key":"722_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/ep161365.Gl","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Pract: Off J Am College Endocrinol Am Assoc Clin Endocrinol. 2016;22(Suppl 3):1\u2013203. https:\/\/doi.org\/10.4158\/ep161365.Gl.","journal-title":"Endocrine Pract: Off J Am College Endocrinol Am Assoc Clin Endocrinol"},{"issue":"5","key":"722_CR93","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198\u2013225. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.045.","journal-title":"Gastroenterology"},{"key":"722_CR94","doi-asserted-by":"publisher","unstructured":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S113-s24. https:\/\/doi.org\/10.2337\/dc22-S008.","DOI":"10.2337\/dc22-S008"},{"issue":"23","key":"722_CR95","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1161\/cir.0000000000000450","volume":"134","author":"B Bozkurt","year":"2016","unstructured":"Bozkurt B, Aguilar D, Deswal A, et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e535\u201378. https:\/\/doi.org\/10.1161\/cir.0000000000000450.","journal-title":"Circulation"},{"key":"722_CR96","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","journal-title":"Eur Heart J"},{"issue":"11","key":"722_CR97","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/s2213-8587(16)30162-0","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Gregg EW, Jakicic JM, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913\u201321. https:\/\/doi.org\/10.1016\/s2213-8587(16)30162-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"722_CR98","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10741-024-10410-0","volume":"29","author":"J Harrington","year":"2024","unstructured":"Harrington J. Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS. Heart Fail Rev. 2024;29(5):939\u201344. https:\/\/doi.org\/10.1007\/s10741-024-10410-0.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"722_CR99","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/hco.0000000000001117","volume":"39","author":"F Capone","year":"2024","unstructured":"Capone F, Nambiar N, Schiattarella GG. Beyond weight loss: the emerging role of incretin-based treatments in cardiometabolic HFpEF. Curr Opin Cardiol. 2024;39(3):148\u201353. https:\/\/doi.org\/10.1097\/hco.0000000000001117.","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"722_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10741-024-10438-2","volume":"30","author":"TY Wang","year":"2025","unstructured":"Wang TY, Yang Q, Cheng XY, Ding JC, Hu PF. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction. Heart Fail Rev. 2025;30(1):17\u201338. https:\/\/doi.org\/10.1007\/s10741-024-10438-2.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"722_CR101","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1056\/NEJMe2415551","volume":"392","author":"GM Felker","year":"2025","unstructured":"Felker GM. Toward a new SUMMIT in heart failure with preserved ejection fraction. N Engl J Med. 2025;392(5):505\u20136. https:\/\/doi.org\/10.1056\/NEJMe2415551.","journal-title":"N Engl J Med"},{"issue":"10","key":"722_CR102","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","volume":"8","author":"C Withaar","year":"2023","unstructured":"Withaar C, Meems LMG, Nollet EE, et al. The cardioprotective effects of Semaglutide exceed those of dietary weight loss in mice with HFpEF. JACC: Basic to Translational Science. 2023;8(10):1298\u2013314. https:\/\/doi.org\/10.1016\/j.jacbts.2023.05.012.","journal-title":"JACC: Basic to Translational Science"},{"issue":"2","key":"722_CR103","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous Semaglutide vs daily Liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"722_CR104","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf335","author":"Z Liu","year":"2025","unstructured":"Liu Z, Weeldreyer NR, Angadi SS. Incretin receptor agonism, fat-free mass, and cardiorespiratory fitness: a narrative review. J Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1210\/clinem\/dgaf335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"722_CR105","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/s2213-8587(24)00272-9","volume":"12","author":"CM Prado","year":"2024","unstructured":"Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785\u20137. https:\/\/doi.org\/10.1016\/s2213-8587(24)00272-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"722_CR106","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/mco.0000000000001131","volume":"28","author":"A Caturano","year":"2025","unstructured":"Caturano A, Amaro A, Berra CC, Conte C. Sarcopenic obesity and weight loss-induced muscle mass loss. Curr Opin Clin Nutr Metab Care. 2025;28(4):339\u201350. https:\/\/doi.org\/10.1097\/mco.0000000000001131.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"722_CR107","doi-asserted-by":"publisher","DOI":"10.2337\/dbi25-0001","author":"BC Jiang","year":"2025","unstructured":"Jiang BC, Villareal DT. The benefits of exercise training in combination with weight loss therapies. Diabetes. 2025. https:\/\/doi.org\/10.2337\/dbi25-0001.","journal-title":"Diabetes"},{"key":"722_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"issue":"22","key":"722_CR109","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1001\/jama.2023.16620","volume":"330","author":"K Ruder","year":"2023","unstructured":"Ruder K. As Semaglutide\u2019s popularity soars, rare but serious adverse effects are emerging. JAMA. 2023;330(22):2140\u20132. https:\/\/doi.org\/10.1001\/jama.2023.16620.","journal-title":"JAMA"},{"key":"722_CR110","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6058","author":"BJ Katz","year":"2025","unstructured":"Katz BJ, Lee MS, Lincoff NS, et al. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol. 2025. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6058.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"722_CR111","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"722_CR112","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"key":"722_CR113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2024","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"10454","key":"722_CR114","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(24)01498-3.","journal-title":"Lancet"},{"issue":"2","key":"722_CR115","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.122.010453","volume":"17","author":"A Mentias","year":"2024","unstructured":"Mentias A, Desai MY, Aminian A, et al. Trends and outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity. Circ Heart Fail. 2024;17(2):e010453. https:\/\/doi.org\/10.1161\/circheartfailure.122.010453.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"722_CR116","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC: Heart Failure. 2024;12(11):1814\u201326. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.006.","journal-title":"JACC: Heart Failure"},{"key":"722_CR117","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.0038","author":"SJ Greene","year":"2025","unstructured":"Greene SJ, Butler J, Fonarow GC. Simultaneous or rapid initiation of combination therapy for heart failure with preserved ejection fraction. JAMA Cardiol. 2025. https:\/\/doi.org\/10.1001\/jamacardio.2025.0038.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"722_CR118","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.jchf.2024.06.006","volume":"12","author":"AR Vest","year":"2024","unstructured":"Vest AR, Schauer PR, Rodgers JE, et al. Obesity and weight loss strategies for patients with heart failure. JACC Heart Fail. 2024;12(9):1509\u201327. https:\/\/doi.org\/10.1016\/j.jchf.2024.06.006.","journal-title":"JACC Heart Fail"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00722-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00722-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00722-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:26:13Z","timestamp":1768544773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00722-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00722-z","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"33"}}